imatinib mesylate has been researched along with Endomyocardial Fibrosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cochet, H; Hennig, A; Leger, A; Peyrou, J | 1 |
| Abecasis, J; Afonso, C; Gouveia, R; Strong, C; Trabulo, M | 1 |
| Bremerich, J; Winter, L; Zellweger, MJ | 1 |
| Chen, HW; Feng, KF; He, LF; Hu, H; Hua, JS; Li, Q; Ma, LK; Wang, L; Yu, H; Zhou, JL | 1 |
| Akin, C; Cools, J; Gilliland, DG; Klion, AD; Law, MA; Metcalfe, DD; Noel, P; Nutman, TB | 1 |
5 other study(ies) available for imatinib mesylate and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Endomyocardial fibrosis in a context of peritonitis.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Cardiomyopathy, Restrictive; Drug Therapy, Combination; Emergency Service, Hospital; Endomyocardial Fibrosis; Epstein-Barr Virus Infections; Follow-Up Studies; Furosemide; Humans; Image Enhancement; Imatinib Mesylate; Lymphoma; Magnetic Resonance Imaging, Cine; Male; Peritonitis; Thrombolytic Therapy; Tomography, X-Ray Computed; Young Adult | 2017 |
Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia.
Topics: Antineoplastic Agents; Biopsy; Disease Progression; Endocardium; Endomyocardial Fibrosis; Heart Failure; Heart Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Myocardium; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
[Endomyocardial fibrosis in chronic eosinophilic leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Aberrations; Echocardiography; Endocardium; Endomyocardial Fibrosis; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Myocardium; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity.
Topics: Animals; Benzamides; Blood Pressure; Blotting, Western; Desoxycorticosterone; Disease Models, Animal; Endomyocardial Fibrosis; Fibronectins; Fibrosis; Hypertension; Imatinib Mesylate; Male; Nephrectomy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Tenascin; Treatment Outcome | 2012 |
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Base Sequence; Benzamides; Biopsy; Bone Marrow; Chromosomes, Human, Pair 4; Endomyocardial Fibrosis; Eosinophils; Female; Fibrosis; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocytes, Mononuclear; Lung Diseases; Male; Mast Cells; Mastocytosis; Middle Aged; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA; Serine Endopeptidases; Splenomegaly; Tryptases; Vitamin B 12 | 2003 |